| ID | 117413 |
| Author |
Hashimoto, Naoki
Hokkaido University
Yasui-Furukori, Norio
Dokkyo Medical University
Hasegawa, Naomi
National Center of Neurology and Psychiatry
Ishikawa, Shuhei
Hokkaido University
Numata, Shusuke
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Hori, Hikaru
University of Occupational and Environmental Health
Iida, Hitoshi
Fukuoka University
Ichihashi, Kayo
University of Tokyo
Furihata, Ryuji
Kyoto University
Murata, Atsunobu
National Center of Neurology and Psychiatry
Tsuboi, Takashi
Kyorin University
Takeshima, Masahiro
Akita University
Kyou, Yoshitaka
Kitasato University
Komatsu, Hiroshi
Tohoku University
Kubota, Chika
National Center of Neurology and Psychiatry
Ochi, Shinichiro
Ehime University
Takaesu, Yoshikazu
University of the Ryukyus
Usami, Masahide
National Center for Global Health and Medicine
Nagasawa, Tatsuya
Kanazawa Medical University
Hishimoto, Akitoyo
Yokohama City University
Miura, Kenichiro
National Center of Neurology and Psychiatry
Matsumoto, Junya
National Center of Neurology and Psychiatry
Ohi, Kazutaka
Gifu University
Yamada, Hisashi
Hyogo College of Medicine
Inada, Ken
Tokyo Women’s Medical University
Watanabe, Koichiro
Kyorin University
Shimoda, Kazutaka
Dokkyo Medical University
Hashimoto, Ryota
National Center of Neurology and Psychiatry
|
| Keywords | Antipsychotics
Antidepressants
Monopharmacy
Polypharmacy
EGUIDE
|
| Content Type |
Journal Article
|
| Description | Background: Monopharmacy with antipsychotics and antidepressants is the first-line treatment for schizophrenia and major depressive disorder (MDD) in most clinical guidelines, while polypharmacy with psychotropic agents in the treatment of schizophrenia is common in clinical practice. There are no detailed data on the prescription patterns for inpatients with mental illness with reliable diagnoses made by treating psychiatrists.
Methods: We gathered prescription data at discharge from 2177 patients with schizophrenia and 1238 patients with MDD from October 2016 to March 2018. Results: The patients with schizophrenia aged between 60 and 79 were prescribed lower doses of antipsychotics and hypnotics/anxiolytics than those aged between 40 and 59. There were significant differences between the prescription rate of antipsychotics in the patients with schizophrenia and that of antidepressants in the patients with MDD. The frequency of concomitant drugs such as anti-Parkinson drugs, anxiolytics/hypnotics and mood stabilizers in the subjects with schizophrenia prescribed antipsychotic polypharmacy was significantly higher than that with monotherapy. For the patients with schizophrenia, olanzapine, risperidone, aripiprazole, quetiapine, and blonanserin were the five most prescribed antipsychotics. For the patients with MDD, mirtazapine, duloxetine, escitalopram, trazodone and sertraline were the five most prescribed antidepressants. Conclusions: Our results showed the use of high doses of antipsychotics, high percentages of antipsychotic polypharmacy and concurrent use of hypnotics/anxiolytics in patients with schizophrenia. Notably, these data were collected before intensive instruction regarding the guidelines; therefore, we need to assess the change in the prescription pattern post guideline instruction. |
| Journal Title |
Asian Journal of Psychiatry
|
| ISSN | 18762018
|
| NCID | AA12793899
|
| Publisher | Elsevier
|
| Volume | 63
|
| Start Page | 102744
|
| Published Date | 2021-07-15
|
| Rights | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
|
| EDB ID | |
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
